Intermittierende Androgendeprivation

Abstract

Studienname Studienkoordinator Patienteneinschluû AP 06/95 (EC 507) U. W. Tunn PSA-Progression nach Radikaler Prostatektomie AP 17/95 J. E. Altwein M1 AP 19/96 (EC 210) J. M. Wolff D2/M1a

Ultraschall-Elastographie der Prostata

“…[Babaian et al, 1992] Bezüglich Prostatakarzinom. [Catalona et al, 1999, Walsh et al, 1994, Zincke et al, 1994 Bei [Tunn, et al, 2000] Die maximale Androgenblockade kombiniert ein LH-RH-Analogon mit einem nebenwirkungsarmen reinen Antiandrogen (z.B. Flutamid).…”

Intermittent Androgen Blockade in Prostate Cancer: Rationale and Clinical Experience

“…However, there may be other biologic markers that will prove more reliable, such as the detection of circulating CaP cell in peripheral blood using reverse transcriptase–polymerase chain reaction (RT–PCR) for either PSA or PSMA mRNA. Tunn et al [39]observed that the RT–PCR for PSA becomes positive before the serum PSA begins to rise. One might speculate that RT–PCR may be a more sensitive marker for monitoring patients on intermittent androgen blockade.…”